Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

By Lauren Pelley, CBC News, RCI Provinces taking different approaches, many Canadians may be paying out of pocket Respiratory syncytial virus, or RSV (new window), isn’t always top of mind during the ...

Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...